These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

476 related items for PubMed ID: 26493206

  • 1. Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size.
    Kurland BF, Muzi M, Peterson LM, Doot RK, Wangerin KA, Mankoff DA, Linden HM, Kinahan PE.
    J Nucl Med; 2016 Feb; 57(2):226-30. PubMed ID: 26493206
    [Abstract] [Full Text] [Related]

  • 2. SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences.
    Beaulieu S, Kinahan P, Tseng J, Dunnwald LK, Schubert EK, Pham P, Lewellen B, Mankoff DA.
    J Nucl Med; 2003 Jul; 44(7):1044-50. PubMed ID: 12843218
    [Abstract] [Full Text] [Related]

  • 3. Comparison of prone versus supine 18F-FDG-PET of locally advanced breast cancer: Phantom and preliminary clinical studies.
    Williams JM, Rani SD, Li X, Arlinghaus LR, Lee TC, MacDonald LR, Partridge SC, Kang H, Whisenant JG, Abramson RG, Linden HM, Kinahan PE, Yankeelov TE.
    Med Phys; 2015 Jul; 42(7):3801-13. PubMed ID: 26133582
    [Abstract] [Full Text] [Related]

  • 4. Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF.
    Doot RK, Dunnwald LK, Schubert EK, Muzi M, Peterson LM, Kinahan PE, Kurland BF, Mankoff DA.
    J Nucl Med; 2007 Jun; 48(6):920-5. PubMed ID: 17504870
    [Abstract] [Full Text] [Related]

  • 5. Test-Retest Variability in Lesion SUV and Lesion SUR in 18F-FDG PET: An Analysis of Data from Two Prospective Multicenter Trials.
    Hofheinz F, Apostolova I, Oehme L, Kotzerke J, van den Hoff J.
    J Nucl Med; 2017 Nov; 58(11):1770-1775. PubMed ID: 28473598
    [Abstract] [Full Text] [Related]

  • 6. Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.
    Visser EP, Philippens ME, Kienhorst L, Kaanders JH, Corstens FH, de Geus-Oei LF, Oyen WJ.
    J Nucl Med; 2008 Jun; 49(6):892-8. PubMed ID: 18483085
    [Abstract] [Full Text] [Related]

  • 7. Spatial and temporal heterogeneity of regional myocardial uptake in patients without heart disease under fasting conditions on repeated whole-body 18F-FDG PET/CT.
    Inglese E, Leva L, Matheoud R, Sacchetti G, Secco C, Gandolfo P, Brambilla M, Sambuceti G.
    J Nucl Med; 2007 Oct; 48(10):1662-9. PubMed ID: 17873124
    [Abstract] [Full Text] [Related]

  • 8. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
    Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps ME, Silverman DH.
    J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
    [Abstract] [Full Text] [Related]

  • 9. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients.
    Dimitrakopoulou-Strauss A, Strauss L.
    Hell J Nucl Med; 2006 Jun; 9(1):10-21. PubMed ID: 16617388
    [Abstract] [Full Text] [Related]

  • 10. Does PET SUV Harmonization Affect PERCIST Response Classification?
    Quak E, Le Roux PY, Lasnon C, Robin P, Hofman MS, Bourhis D, Callahan J, Binns DS, Desmonts C, Salaun PY, Hicks RJ, Aide N.
    J Nucl Med; 2016 Nov; 57(11):1699-1706. PubMed ID: 27283930
    [Abstract] [Full Text] [Related]

  • 11. Variability and uncertainty of 18F-FDG PET imaging protocols for assessing inflammation in atherosclerosis: suggestions for improvement.
    Huet P, Burg S, Le Guludec D, Hyafil F, Buvat I.
    J Nucl Med; 2015 Apr; 56(4):552-9. PubMed ID: 25722452
    [Abstract] [Full Text] [Related]

  • 12. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
    Anderson CM, Chang T, Graham MM, Marquardt MD, Button A, Smith BJ, Menda Y, Sun W, Pagedar NA, Buatti JM.
    Int J Radiat Oncol Biol Phys; 2015 Mar 01; 91(3):472-9. PubMed ID: 25680593
    [Abstract] [Full Text] [Related]

  • 13. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).
    Specht JM, Tam SL, Kurland BF, Gralow JR, Livingston RB, Linden HM, Ellis GK, Schubert EK, Dunnwald LK, Mankoff DA.
    Breast Cancer Res Treat; 2007 Sep 01; 105(1):87-94. PubMed ID: 17268819
    [Abstract] [Full Text] [Related]

  • 14. Towards real-time topical detection and characterization of FDG dose infiltration prior to PET imaging.
    Williams JM, Arlinghaus LR, Rani SD, Shone MD, Abramson VG, Pendyala P, Chakravarthy AB, Gorge WJ, Knowland JG, Lattanze RK, Perrin SR, Scarantino CW, Townsend DW, Abramson RG, Yankeelov TE.
    Eur J Nucl Med Mol Imaging; 2016 Dec 01; 43(13):2374-2380. PubMed ID: 27557845
    [Abstract] [Full Text] [Related]

  • 15. Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET.
    Stahl A, Ott K, Schwaiger M, Weber WA.
    Eur J Nucl Med Mol Imaging; 2004 Nov 01; 31(11):1471-8. PubMed ID: 15257418
    [Abstract] [Full Text] [Related]

  • 16. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
    Hustinx R, Lemaire C, Jerusalem G, Moreau P, Cataldo D, Duysinx B, Aerts J, Fassotte MF, Foidart J, Luxen A.
    J Nucl Med; 2003 Apr 01; 44(4):533-9. PubMed ID: 12679396
    [Abstract] [Full Text] [Related]

  • 17. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.
    Hashimoto Y, Tsujikawa T, Kondo C, Maki M, Momose M, Nagai A, Ohnuki T, Nishikawa T, Kusakabe K.
    J Nucl Med; 2006 Mar 01; 47(3):426-31. PubMed ID: 16513611
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET/CT: comparison with angiogenesis markers and prognostic factors.
    Cochet A, Pigeonnat S, Khoury B, Vrigneaud JM, Touzery C, Berriolo-Riedinger A, Dygai-Cochet I, Toubeau M, Humbert O, Coudert B, Fumoleau P, Arnould L, Brunotte F.
    J Nucl Med; 2012 Apr 01; 53(4):512-20. PubMed ID: 22343501
    [Abstract] [Full Text] [Related]

  • 19. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter.
    Spence AM, Muzi M, Mankoff DA, O'Sullivan SF, Link JM, Lewellen TK, Lewellen B, Pham P, Minoshima S, Swanson K, Krohn KA.
    J Nucl Med; 2004 Oct 01; 45(10):1653-9. PubMed ID: 15471829
    [Abstract] [Full Text] [Related]

  • 20. Simplified kinetic analysis of tumor 18F-FDG uptake: a dynamic approach.
    Sundaram SK, Freedman NM, Carrasquillo JA, Carson JM, Whatley M, Libutti SK, Sellers D, Bacharach SL.
    J Nucl Med; 2004 Aug 01; 45(8):1328-33. PubMed ID: 15299057
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.